PMID- 36717953
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230202
IS  - 1758-5996 (Print)
IS  - 1758-5996 (Electronic)
IS  - 1758-5996 (Linking)
VI  - 15
IP  - 1
DP  - 2023 Jan 30
TI  - Non-altered incretin secretion in women with impaired fasting plasma glucose in 
      the early stage of pregnancy: a case control study.
PG  - 12
LID - 10.1186/s13098-023-00981-7 [doi]
LID - 12
AB  - BACKGROUNDS: Glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic 
      peptide (GIP) may be involved in pathogenesis of gestational diabetes mellitus 
      (GDM). The aim was to compare GLP-1 and GIP production in fasting state and 
      during 3 h mixed meal tolerance test (MMTT) measured by mean area under the curve 
      (AUC) between pregnant women with normal and impaired fasting glucose in an early 
      phase of pregnancy, and healthy non-pregnant controls. METHODS: This study was 
      undertaken as a case-control study. Repeated measurement of fasting plasma 
      glucose >/= 5.1 mmol/L and < 7.0 mmol/L during the first trimester of pregnancy and 
      exclusion of overt diabetes according to IADSPG criteria was used to find women 
      with impaired fasting glucose (n = 22). Age-matched controls consisted of healthy 
      pregnant (n = 25) and non-pregnant (n = 24) women. In addition to incretins, 
      anthropometric parameters and markers of insulin resistance and beta-cell 
      function were assessed. Variables were summarized as median (interquartile 
      range). RESULTS: Fasting GLP-1 and GIP concentration or their AUC during MMTT did 
      not significantly differ between pregnant women with impaired fasting plasma 
      glucose [GLP-1(AUC) 19.0 (53.1) and GIP(AUC) 302 (100) pg/mL/min] and healthy 
      pregnant women [GLP-1(AUC) 16.7 (22.3) and GIP(AUC) 297 (142) pg/mL/min] or 
      non-pregnant controls [GLP-1(AUC) 16.8 (9.8) and for GIP(AUC) 313 (98) 
      pg/mL/min]. Although women with impaired fasting glucose were more obese and 
      showed decreased beta-cell function, there were not significant correlations 
      between incretin production and parameters of insulin secretion, insulin 
      resistance, or obesity. CONCLUSIONS: Women with impaired fasting plasma glucose 
      did not show altered incretin production in the first trimester of pregnancy. In 
      contrast to type 2 diabetes, impaired incretin secretion does not seem to play a 
      major role in the early development of GDM.
CI  - (c) 2023. The Author(s).
FAU - Krystynik, Ondrej
AU  - Krystynik O
AD  - Third Department of Internal Medicine - Nephrology, Rheumatology and 
      Endocrinology, University Hospital Olomouc and Faculty of Medicine and Dentistry, 
      Palacky University, I. P. Pavlova 6, 77900, Olomouc, Czech Republic.
FAU - Karasek, David
AU  - Karasek D
AD  - Third Department of Internal Medicine - Nephrology, Rheumatology and 
      Endocrinology, University Hospital Olomouc and Faculty of Medicine and Dentistry, 
      Palacky University, I. P. Pavlova 6, 77900, Olomouc, Czech Republic. 
      david.karasek@fnol.cz.
FAU - Kahle, Michal
AU  - Kahle M
AD  - Department of Data Science, Institute for Clinical and Experimental Medicine, 
      Videnska 1958,140 21, Prague, Czech Republic.
FAU - Kubickova, Veronika
AU  - Kubickova V
AD  - Department of Clinical Biochemistry, University Hospital Olomouc, I. P. Pavlova 
      6, 77900, Olomouc, Czech Republic.
FAU - Macakova, Dominika
AU  - Macakova D
AD  - Third Department of Internal Medicine - Nephrology, Rheumatology and 
      Endocrinology, University Hospital Olomouc and Faculty of Medicine and Dentistry, 
      Palacky University, I. P. Pavlova 6, 77900, Olomouc, Czech Republic.
FAU - Cibickova, Lubica
AU  - Cibickova L
AD  - Third Department of Internal Medicine - Nephrology, Rheumatology and 
      Endocrinology, University Hospital Olomouc and Faculty of Medicine and Dentistry, 
      Palacky University, I. P. Pavlova 6, 77900, Olomouc, Czech Republic.
FAU - Mraz, Milos
AU  - Mraz M
AD  - Diabetes Centre, Institute for Clinical and Experimental Medicine, Videnska 1958, 
      140 21, Prague, Czech Republic.
FAU - Haluzik, Martin
AU  - Haluzik M
AD  - Diabetes Centre, Institute for Clinical and Experimental Medicine, Videnska 1958, 
      140 21, Prague, Czech Republic.
LA  - eng
GR  - NV18-01-00139/Agentura pro zdravotnicky vy/
GR  - MH CZ DRO (FNOl, 00098892)/Ministerstvo Zdravotnictvi Ceske Republiky/
GR  - IGA LF 2022 003/Palacky University Olomouc, Faculty of Medicine and Dentistry/
GR  - LX22NPO5104/National Institute for Research of Metabolic and Cardiovascular 
      Diseases (Program EXCELES)/
PT  - Journal Article
DEP - 20230130
PL  - England
TA  - Diabetol Metab Syndr
JT  - Diabetology & metabolic syndrome
JID - 101488958
PMC - PMC9885569
OTO - NOTNLM
OT  - Gestational diabetes
OT  - Glucagon
OT  - Glucagon-like peptide 1
OT  - Glucose-dependent insulinotropic peptide
OT  - Meal test
COIS- All authors declare no conflicts of interest.
EDAT- 2023/02/01 06:00
MHDA- 2023/02/01 06:01
PMCR- 2023/01/30
CRDT- 2023/01/31 00:08
PHST- 2022/09/27 00:00 [received]
PHST- 2023/01/06 00:00 [accepted]
PHST- 2023/01/31 00:08 [entrez]
PHST- 2023/02/01 06:00 [pubmed]
PHST- 2023/02/01 06:01 [medline]
PHST- 2023/01/30 00:00 [pmc-release]
AID - 10.1186/s13098-023-00981-7 [pii]
AID - 981 [pii]
AID - 10.1186/s13098-023-00981-7 [doi]
PST - epublish
SO  - Diabetol Metab Syndr. 2023 Jan 30;15(1):12. doi: 10.1186/s13098-023-00981-7.